Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024

$NVRO
Medical/Dental Instruments
Health Care
Get the next $NVRO alert in real time by email

REDWOOD CITY, Calif., Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 after the market closes on Wednesday, February 21, 2024.

The company will also host a conference call on February 21, 2024 to discuss its financial results. The call will begin at 1:30 pm PT / 4:30 pm ET. Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S. or +1 (240) 789-2728 internationally, using conference ID: 3583097. A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at Events & Presentations. The live webcast should be accessed 10 minutes prior to the conference call start time.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 100,000 patients globally. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy.

Nevro recently added a minimally invasive treatment option for patients suffering from chronic sacroiliac joint ("SI joint") pain and now provides the most comprehensive portfolio of products in the SI joint fusion space, designed to meet the preferences of physicians and varying patient needs in order to improve outcomes and quality of life for patients.

Senza®, Senza II®, Senza Omnia®, and HFX iQ™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support services provide every patient with HFX Coach™ support throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.

SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents.

To learn more about Nevro, connect with us on LinkedIn, X, Facebook, and Instagram.

Investors and Media:

Angie McCabe

Vice President, Investor Relations & Corporate Communications

angeline.mccabe@nevro.com

.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-to-report-fourth-quarter-and-full-year-2023-financial-results-and-host-conference-call-on-february-21-2024-302046818.html

SOURCE Nevro Corp.

Get the next $NVRO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NVRO

DatePrice TargetRatingAnalyst
2/10/2025$4.50 → $5.85Underperform → Hold
Jefferies
2/7/2025$6.00 → $5.85Neutral → Overweight
Piper Sandler
12/3/2024$5.00Equal Weight
Wells Fargo
12/2/2024$9.00 → $4.00Equal-Weight → Underweight
Morgan Stanley
8/9/2024Sell → Neutral
Citigroup
8/8/2024Underperform → Peer Perform
Wolfe Research
8/7/2024Mkt Outperform → Mkt Perform
JMP Securities
8/7/2024Neutral → Underweight
JP Morgan
More analyst ratings

$NVRO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

    REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care
  • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

    AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care
  • Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

    REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induceme

    $NVRO
    Medical/Dental Instruments
    Health Care

$NVRO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$NVRO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$NVRO
SEC Filings

See more

$NVRO
Leadership Updates

Live Leadership Updates

See more
  • Nevro Enters Into Cooperation Agreement With Engaged Capital

    Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi

    $NVRO
    Medical/Dental Instruments
    Health Care
  • Nevro Appoints Jon R. Shear as Vice President, Corporate Development

    REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately.   "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and

    $NVRO
    Medical/Dental Instruments
    Health Care
  • Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications

    REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately.   "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a

    $NVRO
    Medical/Dental Instruments
    Health Care

$NVRO
Financials

Live finance-specific insights

See more
  • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

    REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care
  • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

    AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

    $GMED
    $NVRO
    Medical/Dental Instruments
    Health Care
  • Nevro Reports Third-Quarter 2024 Financial Results

    Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma

    $NVRO
    Medical/Dental Instruments
    Health Care

$NVRO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more